Exploiting the kinetic interplay between GPIbα-VWF binding interfaces to regulate hemostasis and thrombosis

Blood

Volumn 124, Issue 25, 2014, Pages 3799-3807

  Chen, Jianchung ^a   Zhou, Hairu ^a   Diacovo, Alexander ^a   Zheng, X Long ^b   Emsley, Jonas ^c   Diacovo, Thomas G ^a  

^a NewYork Presbyterian Hospital   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^c UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN IB ALPHA; VON WILLEBRAND FACTOR; PROTEIN BINDING; THROMBIN RECEPTOR;

AMINO ACID SUBSTITUTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD CLOTTING; CONTROLLED STUDY; CRYSTAL STRUCTURE; CYBERNETICS; GAIN OF FUNCTION MUTATION; GENETIC TRANSCRIPTION; HEMOSTASIS; IN VIVO STUDY; KINETICS; MOUSE; NONHUMAN; PHENOTYPE; PROTEIN FUNCTION; REGULATORY MECHANISM; SHEAR RATE; STATIC ELECTRICITY; THROMBOCYTE ADHESION; THROMBOSIS; ANIMAL; BINDING SITE; BLOOD; C57BL MOUSE; CHEMICAL STRUCTURE; CHEMISTRY; GENETICS; HUMAN; KNOCKOUT MOUSE; METABOLISM; MUTATION; PROTEIN TERTIARY STRUCTURE; THROMBOCYTE;

ANIMALS; BINDING SITES; BLOOD PLATELETS; HEMOSTASIS; HUMANS; KINETICS; MICE, INBRED C57BL; MICE, KNOCKOUT; MODELS, MOLECULAR; MUTATION; PLATELET ADHESIVENESS; PLATELET GLYCOPROTEIN GPIB-IX COMPLEX; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; THROMBOSIS; VON WILLEBRAND FACTOR;

EID: 84919635656     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-04-569392     Document Type: Article

References (49)

1. Ruggeri ZM, Orje JN, Habermann R, Federici AB, Reininger AJ. Activation-independent platelet adhesion and aggregation under elevated shear stress. Blood. 2006;108(6):1903-1910.
2. Sakariassen KS, Bolhuis PA, Sixma JJ. Human blood platelet adhesion to artery subendothelium is mediated by factor VIII-Von Willebrand factor bound to the subendothelium. Nature. 1979;279(5714):636-638.
3. Nichols WC, Ginsburg D. von Willebrand disease. Medicine (Baltimore). 1997;76(1):1-20.
4. Sadler JE. New concepts in von Willebrand disease. Annu Rev Med. 2005;56:173-191.
5. Cruz MA, Diacovo TG, Emsley J, Liddington R, Handin RI. Mapping the glycoprotein Ib-binding site in the von willebrand factor A1 domain. J Biol Chem. 2000;275(25):19098-19105.
6. Piétu G, Meulien P, Cherel G, et al. Production in escherichia coli of a biologically active subfragment of von Willebrand factor corresponding to the platelet glycoprotein Ib, collagen and heparin binding domains. Biochem Biophys Res Commun. 1989;164(3):1339-1347.
7. Savage B, Saldívar E, Ruggeri ZM. Initiation of platelet adhesion by arrest onto fibrinogen or translocation on von Willebrand factor. Cell. 1996;84(2):289-297.
8. Sugimoto M, Ricca G, Hrinda ME, et al. Functional modulation of the isolated glycoprotein Ib binding domain of von Willebrand factor expressed in Escherichia coli. Biochemistry. 1991;30(21):5202-5209.
9. Dumas JJ, Kumar R, McDonagh T, et al. Crystal structure of the wild-type von Willebrand factor A1-glycoprotein Ibalpha complex reveals conformation differences with a complex bearing von Willebrand disease mutations. J Biol Chem. 2004;279(22):23327-23334.
10. Huizinga EG, Tsuji S, Romijn RA, et al. Structures of glycoprotein Ibalpha and its complex with von Willebrand factor A1 domain. Science. 2002;297(5584):1176-1179.
11. Fukuda K, Doggett T, Laurenzi IJ, Liddington RC, Diacovo TG. The snake venom protein botrocetin acts as a biological brace to promote dysfunctional platelet aggregation. Nat Struct Mol Biol. 2005;12(2):152-159.
12. Blenner MA, Dong X, Springer TA. Structural basis of regulation of von Willebrand factor binding to glycoprotein Ib. J Biol Chem. 2014;289(9):5565-5579.
13. Benard SA, Smith TM, Cunningham K, et al. Identification of peptide antagonists to glycoprotein Ibalpha that selectively inhibit von Willebrand factor dependent platelet aggregation. Biochemistry. 2008;47(16):4674-4682.
14. McEwan PA, Andrews RK, Emsley J. Glycoprotein Ibalpha inhibitor complex structure reveals a combined steric and allosteric mechanism of von Willebrand factor antagonism. Blood. 2009;114(23):4883-4885.
15. Lenting PJ, Pegon JN, Groot E, de Groot PG. Regulation of von Willebrand factor-platelet interactions. Thromb Haemost. 2010;104(3):449-455.
16. Ulrichts H, Udvardy M, Lenting PJ, et al. Shielding of the A1 domain by the D'D3 domains of von Willebrand factor modulates its interaction with platelet glycoprotein Ib-IX-V. J Biol Chem. 2006;281(8):4699-4707.
17. Hulstein JJ, Lenting PJ, de Laat B, Derksen RH, Fijnheer R, de Groot PG. beta2-Glycoprotein I inhibits von Willebrand factor dependent platelet adhesion and aggregation. Blood. 2007;110(5):1483-1491.
18. Dong JF, Berndt MC, Schade A, McIntire LV, Andrews RK, López JA. Ristocetin-dependent, but not botrocetin-dependent, binding of von Willebrand factor to the platelet glycoprotein Ib-IX-V complex correlates with shear-dependent interactions. Blood. 2001;97(1):162-168.
19. Schneider SW, Nuschele S, Wixforth A, et al. Shear-induced unfolding triggers adhesion of von Willebrand factor fibers. Proc Natl Acad Sci USA. 2007;104(19):7899-7903.
20. Arya M, Kolomeisky AB, Romo GM, Cruz MA, López JA, Anvari B. Dynamic force spectroscopy of glycoprotein Ib-IX and von Willebrand factor. Biophys J. 2005;88(6):4391-4401.
21. Doggett TA, Girdhar G, Lawshé A, et al. Selectin-like kinetics and biomechanics promote rapid platelet adhesion in flow: the GPIb(a)-vWF tether bond. Biophys J. 2002;83(1):194-205.
22. Doggett TA, Girdhar G, Lawshe A, et al. Alterations in the intrinsic properties of the GPIbalpha-VWF tether bond define the kinetics of the platelet-type von Willebrand disease mutation, Gly233Val. Blood. 2003;102(1):152-160.
23. Kumar RA, Dong JF, Thaggard JA, Cruz MA, López JA, McIntire LV. Kinetics of GPIbalpha-vWF-A1 tether bond under flow: effect of GPIbalpha mutations on the association and dissociation rates. Biophys J. 2003;85(6):4099-4109.
24. Ju L, Dong JF, Cruz MA, Zhu C. The N-terminal flanking region of the A1 domain regulates the force-dependent binding of von Willebrand factor to platelet glycoprotein Iba. J Biol Chem. 2013;288(45):32289-32301.
25. Dufrêne YF, Evans E, Engel A, Helenius J, Gaub HE, Müller DJ. Five challenges to bringing single-molecule force spectroscopy into living cells. Nat Methods. 2011;8(2):123-127.
26. Neuman KC, Nagy A. Single-molecule force spectroscopy: optical tweezers, magnetic tweezers and atomic force microscopy. Nat Methods. 2008;5(6):491-505.
27. Weisel JW, Shuman H, Litvinov RI. Protein-protein unbinding induced by force: single-molecule studies. Curr Opin Struct Biol. 2003;13(2):227-235.
28. Chen J, Tan K, Zhou H, et al. Modifying murine von Willebrand factor A1 domain for in vivo assessment of human platelet therapies. Nat Biotechnol. 2008;26(1):114-119.
29. Cao W, Krishnaswamy S, Camire RM, Lenting PJ, Zheng XL. Factor VIII accelerates proteolytic cleavage of von Willebrand factor by ADAMTS13. Proc Natl Acad Sci USA. 2008;105(21):7416-7421.
30. Laje P, Shang D, Cao W, et al. Correction of murine ADAMTS13 deficiency by hematopoietic progenitor cell-mediated gene therapy. Blood. 2009;113(10):2172-2180.
31. Niiya M, Endo M, Shang D, et al. Correction of ADAMTS13 deficiency by in utero gene transfer of lentiviral vector encoding ADAMTS13 genes. Mol Ther. 2009;17(1):34-41.
32. Magallon J, Chen J, Rabbani L, et al. Humanized mouse model of thrombosis is predictive of the clinical efficacy of antiplatelet agents. Circulation. 2011;123(3):319-326.
33. Federici AB, Mannucci PM, Stabile F, et al. A type 2b von Willebrand disease mutation (Ile546->Val) associated with an unusual phenotype. Thromb Haemost. 1997;78(3):1132-1137.
34. Jenkins PV, Pasi KJ, Perkins SJ. Molecular modeling of ligand and mutation sites of the type A domains of human von Willebrand factor and their relevance to von Willebrand's disease. Blood. 1998;91(6):2032-2044.
35. Fukuda K, Doggett TA, Bankston LA, Cruz MA, Diacovo TG, Liddington RC. Structural basis of von Willebrand factor activation by the snake toxin botrocetin. Structure. 2002;10(7):943-950.
36. Bell GI. Models for the specific adhesion of cells to cells. Science. 1978;200(4342):618-627.
37. Uz B, Arslan E, Laurenzi IJ. Maximum likelihood estimation of the kinetics of receptor-mediated adhesion. J Theor Biol. 2010;262(3):478-487.
38. Navarrete AM, Casari C, Legendre P, et al. A murine model to characterize the antithrombotic effect of molecules targeting human von Willebrand factor. Blood. 2012;120(13):2723-2732.
39. Radley JM, Hodgson GS, Levin J. Platelet production after administration of antiplatelet serum and 5-fluorouracil. Blood. 1980;55(1):164-166.
40. Flood VH, Gill JC, Morateck PA, et al. Common VWF exon 28 polymorphisms in African Americans affecting the VWF activity assay by ristocetin cofactor. Blood. 2010;116(2):280-286.
41. Chen W, Evans EA, McEver RP, Zhu C. Monitoring receptor-ligand interactions between surfaces by thermal fluctuations. Biophys J. 2008;94(2):694-701.
42. Evans EA, Calderwood DA. Forces and bond dynamics in cell adhesion. Science. 2007;316(5828):1148-1153.
43. Thomas WE. Mechanochemistry of receptorligand bonds. Curr Opin Struct Biol. 2009;19(1):50-55.
44. Yago T, Lou J, Wu T, et al. Platelet glycoprotein Ibalpha forms catch bonds with human WT vWF but not with type 2B von Willebrand disease vWF. J Clin Invest. 2008;118(9):3195-3207.
45. Coburn LA, Damaraju VS, Dozic S, Eskin SG, Cruz MA, McIntire LV. GPIba-vWF rolling under shear stress shows differences between type 2B and 2M von Willebrand disease. Biophys J. 2011;100(2):304-312.
46. Sanders WE, Read MS, Reddick RL, Garris JB, Brinkhous KM. Thrombotic thrombocytopenia with von Willebrand factor deficiency induced by botrocetin. An animal model. Lab Invest. 1988;59(4):443-452.
47. Sadler JE. Biomedicine. Contact - how platelets touch von Willebrand factor. Science. 2002;297(5584):1128-1129.
48. Wadanoli M, Sako D, Shaw GD, et al. The von Willebrand factor antagonist (GPG-290) prevents coronary thrombosis without prolongation of bleeding time. Thromb Haemost. 2007;98(2):397-405.
49. Knöbl P, Jilma B, Gilbert JC, Hutabarat RM, Wagner PG, Jilma-Stohlawetz P. Anti-von Willebrand factor aptamer ARC1779 for refractory thrombotic thrombocytopenic purpura. Transfusion. 2009;49(10):2181-2185.